血小板与淋巴细胞比值（PLR）和中性粒细胞与淋巴细胞比值（NLR）能否帮助预测复发性胶质母细胞瘤患者的结局？
Can Platelet-to-Lymphocyte Ratio (PLR) and Neutrophil-to-Lymphocyte Ratio (NLR) Help Predict Outcomes of Patients With Recurrent Glioblastoma?
机构信息
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
Department of Radioneurosurgery, Romodanov Neurosurgery Institute, Kyiv, Ukraine.
出版信息
In Vivo. 2024 Sep-Oct;38(5):2341-2348. doi: 10.21873/invivo.13700.
BACKGROUND/AIM: In patients with recurrent glioblastoma, very little data are available regarding the prognostic value of platelet-to-lymphocyte (PLR) and neutrophil-to-lymphocyte (NLR) ratios. This study investigated potential associations between PLR or NLR and treatment outcomes.
PATIENTS AND METHODS
PLR and NLR at diagnosis of recurrence plus 10 additional characteristics were retrospectively analyzed for associations with progression-free survival (PFS) and overall survival (OS) in 75 patients with recurrent glioblastoma.
RESULTS
On multivariate analyses, maximal cumulative diameter of recurrent lesion(s) <40 mm (p=0.015) and systemic therapy (p<0.001) were associated with improved PFS. On multivariate analysis of OS, improved outcomes were significantly associated with PLR ≤150 (p=0.029), maximal cumulative diameter <40 mm (p=0.030), and systemic therapy (p=0.010).
CONCLUSION
In addition to other characteristics, PLR at the time of recurrence was identified as an independent predictor of OS in patients with recurrent glioblastoma. PLR may be useful when designing personalized treatment approaches or clinical trials.
背景/目的：在复发性胶质母细胞瘤患者中，关于血小板与淋巴细胞（PLR）和中性粒细胞与淋巴细胞（NLR）比值的预后价值的数据很少。本研究探讨了 PLR 或 NLR 与治疗结果之间的潜在关联。
患者和方法
回顾性分析了 75 例复发性胶质母细胞瘤患者复发时的 PLR 和 NLR 以及另外 10 个特征，以评估其与无进展生存期（PFS）和总生存期（OS）的相关性。
结果
多变量分析显示，复发性病变的最大累积直径<40mm（p=0.015）和全身治疗（p<0.001）与改善的 PFS 相关。OS 的多变量分析显示，PLR≤150（p=0.029）、最大累积直径<40mm（p=0.030）和全身治疗（p=0.010）与预后改善显著相关。
结论
除了其他特征外，复发性胶质母细胞瘤患者的 PLR 被确定为 OS 的独立预测因子。PLR 在设计个性化治疗方法或临床试验时可能有用。
Zotero 插件